Serum PCSK9 in relation to coronary near-infrared spectroscopy-derived lipid core burden index and long-term cardiovascular outcome [ATHEROREMO-NIRS substudy].

Back

ESC Premium Access

Serum PCSK9 in relation to coronary near-infrared spectroscopy-derived lipid core burden index and long-term cardiovascular outcome [ATHEROREMO-NIRS substudy].

Session: PCSK9: Beyond lipid - lowering effects?

Topic: Atherosclerosis

Speaker: Miss S. Anroedh (Rotterdam, NL)

Event: ESC Congress 2017

Congress Presentation

About the speaker

Miss Sharda Suzan Anroedh

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

0 follower

3 more presentations in this session

State of the Art: PCSK9 - Beyond lipid-lowering effects?

Speaker: Professor U. Landmesser (Berlin, DE)

Access

Slides

Video

PCSK9 beyond its role in cholesterol homeostasis: co-activator of platelet function

Speaker: Assistant Professor M. Camera (Milan, IT)

PCSK9 inhibition: what do we know from clinical trials?

Speaker: Professor J. Chapman (Paris, FR)

Access

Slides

Video

Access the full session

PCSK9: Beyond lipid - lowering effects?

Speakers: Miss S. Anroedh, Professor U. Landmesser, Assistant Professor M. Camera, Professor J. Chapman

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

Serum PCSK9 in relation to coronary near-infrared spectroscopy-derived lipid core burden index and long-term cardiovascular outcome [ATHEROREMO-NIRS substudy].

About the speaker

Miss Sharda Suzan Anroedh

3 more presentations in this session

State of the Art: PCSK9 - Beyond lipid-lowering effects?

PCSK9 beyond its role in cholesterol homeostasis: co-activator of platelet function

PCSK9 inhibition: what do we know from clinical trials?

Access the full session

PCSK9: Beyond lipid - lowering effects?

About the event

ESC Congress 2017

ESC 365 is supported by